Accessibility Menu
Translational Development Acquisition Corp. logo

Translational Development Acquisition Corp.(NASDAQ) TDACW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)+775%
5 YearN/A
1 Year+611%
1 Month-5%
$1.75
+6.05%
+0.10Today
Translational Development Acquisition Corp. last closing stock price
MetricPriceDate
Last closeUSD 1.752026-08-31
Translational Development Acquisition Corp. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.85%USD 1.822026-08-24
1 month-5.41%USD 1.852026-07-31
3 month+36.72%USD 1.282026-06-02
Year to date+464.52%USD 0.312025-12-30
1 year+611.09%USD 0.252025-08-27
Since inception+775%USD 0.202025-02-13

Translational Development Acquisition Corp. Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$5.54M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.84 (Low)

Price

$1.75

Volume

2,353

Open

$1.85

Previous Close

$1.75

Daily Range

$1.75 - $1.90

52-Week Range

$0.06 - $2.80

Estimated Earnings Date

N/A

TDACW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Translational Development Acquisition Corp.

Translational Development Acquisition Corp. is a financial services company based in New York, established in 2022. The company is focused on completing a strategic business combination, which may involve mergers, asset acquisitions, or reorganizations with other entities.

Products and Services
  • Strategic business combinations with potential partners
  • Asset acquisition opportunities in various sectors
  • Financial advisory services for mergers and acquisitions
Growth Outlook
  • Market capitalization currently stands at approximately $307 million
  • Recent quarterly net income of $1.33 million indicates potential profitability
  • Strong interest income trends observed, reaching over $1.8 million in Q3 2025
Financial Highlights
  • Trailing twelve months (TTM) P/E ratio of 37.71 suggests growth potential
  • Net income of $1.33 million reported for Q1 2026
  • Cash and short-term investments total approximately $24,630 as of Q1 2026
Translational Development Acquisition Corp. operates in the shell company sector, primarily focusing on identifying and executing strategic business combinations. The company has shown promising financial indicators, including a recent net income of $1.33 million, which reflects its potential for profitability. The TTM P/E ratio of 37.71 suggests that investors may be willing to pay a premium for future growth, indicating confidence in the company's strategic direction. The company has also demonstrated a strong interest income trend, with over $1.8 million reported in Q3 2025, showcasing its ability to generate revenue through financial activities. With a market capitalization of approximately $307 million, Translational Development Acquisition Corp. is positioned to leverage its resources for future growth opportunities. Overall, the company is actively seeking to finalize a strategic business combination, which could significantly enhance its operational capabilities and market presence. The financial metrics indicate a foundation for potential growth, making it an intriguing option for investors interested in the financial services sector.
AI Generated • Aug 12, 2026

Industry

Capital Markets

Headquarters

New York City, NY 10028, US

TDACW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

3.28%

Return on Capital

-0.54%

Return on Assets

3.52%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

58.20%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

2.35K

Avg. Volume

22.66K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.32M

EBITDA

-$1.32M

Operating Cash Flow

-$849.38K

Capital Expenditure

$0.00

Free Cash Flow

-$849.38K

Cash & ST Invst.

$85.88K

Total Debt

$1.10M

Translational Development Acquisition Corp. Performance Analysis

Translational Development Acquisition Corp. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Translational Development Acquisition Corp. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-308.0%
Q42025-12-31-9.0%
Q12026-03-31-16.5%
Q22026-06-30-27.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

2

N/A

Net Income

$946.98K

-41.7%

EBITDA

-$661.05K

-198.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$85.88K

+143.6%

Total Debt

$1.10M

-79.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.10M

-79.2%

Return on Assets

3.52%

N/A

Return on Invested Capital

-0.85%

N/A

Free Cash Flow

-$338.75K

-97.7%

Operating Cash Flow

-$338.75K

-97.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About TDACW

What is the current price of Translational Development Acquisition Corp.?

Translational Development Acquisition Corp. is trading at $1.75 per share.

What is the 52-week range for Translational Development Acquisition Corp.?

Over the past 52 weeks, Translational Development Acquisition Corp. has traded between $0.06 and $2.80.

How much debt does Translational Development Acquisition Corp. have?

Translational Development Acquisition Corp. total debt is unavailable.

How much cash does Translational Development Acquisition Corp. have on hand?

Translational Development Acquisition Corp. does not have cash on hand data available.

What is Translational Development Acquisition Corp.’s dividend yield?

Translational Development Acquisition Corp. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.